Twist Bioscience Corp TWST
At Twist Bioscience Corporation, we work in service of our customers who are changing the world for the better. 10-K, Item 1
- Headquarters
- South San Francisco, CA
- CEO
- Emily M. Leproust
- Next results
- around Jan 11, 2027
TWST among Health care peers
Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.
What changed
14 new risk paragraphs and 1 accounting fact worth reading about. 10-K filed Nov 17, 2025 against Nov 18, 2024.
Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.
Accounting checks
11 checks on the latest 10-K. Checks, not verdicts.
1fact worth reading about the other 10 checks found nothing to note
-
Receivables growing faster than revenueReceivables +63.4% ($34.9M to $57.0M) vs revenue +20.3% ($313.0M to $376.6M), +43.0 pts apart
-
Cash from operations −$47.6M vs net income −$77.7M (FY ending Sep 30, 2025)
9 more checks with nothing to note
-
Inventory +17.6% ($24.1M to $28.3M) vs revenue +20.3% ($313.0M to $376.6M), -2.7 pts apart
-
Same auditor in both 10-Ks: Ernst & Young LLP
-
No statement of substantial doubt about going concern
-
No 8-K item 4.02 in the last 2 years
-
No NT 10-K or NT 10-Q in the last 2 years
-
The same matters as last year: Revenue recognition
-
No sentence in the 10-K concludes that controls were not effective because of a material weakness
-
No 8-K item 2.06 in the last 2 years
-
No 8-K item 1.03 in the last 2 years
In their words
14 paragraphs in Risk Factors that were not in the 10-K filed Nov 18, 2024. Quoted as filed.
-
Item 1A · new paragraph · not in the 10-K filed Nov 18, 2024 10-K, ITEM 1A
As we continue to grow our business, we will need to implement new systems and software successfully, otherwise our business and our financial condition and results of operations could be adversely affected. We will need to invest in improvements to our operational and IT systems and processes as part of our ongoing effort to improve…
-
Item 1A · new paragraph · not in the 10-K filed Nov 18, 2024 10-K, ITEM 1A
AI capabilities may indicate that it could be a significant disruptor in the synthetic biology industry. For example, AI may reduce customer demand for certain types of gene synthesis.
-
Item 1A · new paragraph · not in the 10-K filed Nov 18, 2024 10-K, ITEM 1A
The global economy has been impacted by geopolitical tensions. For example, new U.S. federal administration has recently imposed significant new tariffs on imports, which, along with other U.S. trade actions, have triggered retaliatory actions by certain affected countries. These geopolitical tensions could result in, among other…
-
Item 1A · new paragraph · not in the 10-K filed Nov 18, 2024 10-K, ITEM 1A
We may not achieve the anticipated benefits from the spin out of our DNA data storage application. In May 2025, we completed the spin out of our DNA data storage application to a new independent company, Atlas Data Storage (“Atlas”), which allows us to focus on our synthetic biology, NGS and biopharma products and services. While we…
New risk paragraphs, against peers
Latest 10-K of each, Health care companies closest in revenue
Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.
Financial performance
Last 4 fiscal years · 10-K XBRL
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | $203.6M | $245.1M | $313.0M | $376.6M |
| Net income | −$217.9M | −$204.6M | −$208.7M | −$77.7M |
| Operating cash flow | −$124.4M | −$142.5M | −$64.1M | −$47.6M |
| Free cash flow | −$226.2M | −$170.3M | −$69.2M | −$75.6M |
Revenue, FY2017 to FY2025
Ten fiscal years, each from its own 10-K · XBRL · USD
$376.6M ▲ 20.3% in FY2025−$77.7M in FY2025−$75.6M in FY2025
Recent filings
7 filings in the last 30 days · SEC EDGAR
-
8-KNov 12, 2026Quarterly results 8-K item 2.02
-
Planned saleNov 3, 2026Green Paula (Officer) gave notice of a planned sale of 1,007 shares worth about $136K Form 144, approximate sale date Nov 3, 2026
-
Planned saleNov 3, 2026Leproust Emily M. (Officer, Director) gave notice of a planned sale of 4,573 shares worth about $619K Form 144, approximate sale date Nov 3, 2026
-
Planned saleNov 3, 2026Cho Dennis (Officer) gave notice of a planned sale of 949 shares worth about $128K Form 144, approximate sale date Nov 3, 2026
-
Planned saleNov 3, 2026Finn Patrick John (Officer) gave notice of a planned sale of 2,565 shares worth about $347K Form 144, approximate sale date Nov 3, 2026
About the company
Twist Bioscience Corp, South San Francisco, CA · from the 10-K filed Nov 17, 2025
At Twist Bioscience Corporation, we work in service of our customers who are changing the world for the better. In fields such as health care, food/agriculture, industrial chemicals/materials and academic research, by using our products, our customers are developing ways to better lives and improve the sustainability of the planet. We believe Twist Bioscience is uniquely positioned to help accelerate their efforts and the faster our customers succeed, the better for all of us.
- Headquarters
- South San Francisco, CA
- Country
- United States
- Reports in
- USD
- Listed on
- Nasdaq
- Fiscal year ends
- September 30
- Last results
- Nov 12, 2026
- Incorporated in
- DE
Email alerts
Sources
The 10-K filed Nov 17, 2025 (open at SEC), compared with the 10-K filed Nov 18, 2024. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.
Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/TWST/export.csv") into a cell.